Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.942 million shares at a price of HKD 1.8776 per share, totaling approximately HKD 5.5239 million [1] - After the reduction, GL Capital Management's remaining shareholding is approximately 39.0995 million shares, representing a holding percentage of 6.64% [1] - The transaction involves other related parties, including Assicurazioni Generali SpA, Li Zhenfu, and Lion River I N.V. [1]

致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 本月底法定/註冊股本總額： HKD 50,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | 李氏大藥廠控股有限公司 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 1,000,000,000 HKD | ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Lee's Pharmaceutical Holdings Limited, which rose over 21% and is currently trading at 21 HKD, with a trading volume of 31.96 million HKD [1] - The company reported a mid-term revenue of 695 million HKD, reflecting a year-on-year increase of 5.5%, driven by strong sales performance of its product portfolio [1] - The net profit attributable to shareholders for the first half of 2025 was 67.185 million HKD, representing a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and improved operational strength [1] Group 2 - The company announced that its subsidiary, Zhaoke Pharmaceutical, received approval for a new indication for its anti-PD-L1 monoclonal antibody, Socazolimab, for use in combination chemotherapy as a first-line treatment for extensive-stage small cell lung cancer [1] - This approval marks the second indication for Socazolimab, following its initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

李氏大药厂(00950)尾盘涨超21%，截至发稿，涨16.02%，报21港元，成交额3195.61万港元。 消息面上，李氏大药厂此前发布中期业绩，该集团取得收益6.95亿港元，同比增加5.5%；主要由集团产 品组合稳健的销售表现所带动。2025年上半年的公司拥有人应占纯利为6718.5万港元，同比增加7.5%。 此表现加强去年确立的可持续增长轨迹，并反映集团进一步巩固营运实力及财务纪律。每股盈利11.41 港仙。 值得注意的是，李氏大药厂7月底公告称，旗下子公司兆科肿瘤申报的抗PD-L1单克隆抗体索卡佐利单 抗新适应症上市申请已获得批准。根据李氏大药厂公开资料可知，该药本次获批的适应症为联合化疗一 线治疗广泛期小细胞肺癌。此举标志着索卡佐利单抗注射液继最初有条件获批用于治疗复发或转移性子 宫颈癌后第二个获批准的适应症。 ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 提名委員會之職權範圍 2. 組 成 * 僅供識別 – 1 – 4.1 提 名 委 員 會 主 席 或（如 其 未 克 出 席）提 名 委 員 會 其 他 成 員（須 為 獨 立 非 執 行 董 事）須 出 席 本 公 司 之 股 東 週 年 大 會，就 股 東 對 提 名 委 員 會 事 務 及 責 任 之 提 問 作 出 回 應。 – 2 – 3.1 提 名 委 員 會 須 每 年 至 少 會 面 一 次。提 名 委 員 會 成 員 可 隨 時 於 認 為 必 要 之 情 況 下 召 開 會 議。 3.2 除 非 獲 提 名 委 員 會 全 體 成 員 豁 免，否 則 須 為 所 有 會 議 發 出 正 式 通 告。 不 論 通 告 期 之 長 短，提 名 委 員 會 成 員 出 席 會 議 將 被 視 作 豁 免 所 需 通 告 規 定 處 理。 3.3 提 名 委 員 會 議 事 所 需 之 法 定 人 數 須 為 兩 名 提 名 委 員 會 成 ...

Group 1 - The company reported a revenue of HKD 695 million for the first half of 2025, representing a year-on-year increase of 5.5% [1] - The net profit for the same period was HKD 67.185 million, showing a year-on-year growth of 7.5% [1] - The company proposed an interim dividend of HKD 0.022 per share [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, reflecting a year-on-year increase of 7.5% [1] - Earnings per share were HKD 0.1141, with an interim dividend proposed at HKD 0.022 per share [1] Revenue Growth Drivers - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with "Qufrile" injection achieving a robust growth of 31.4% and "Buleidining" rising by 12.9% [1] - In the traditional product mix of introduced products, "Fipril" saw a significant growth of 33.3%, regaining its position as the largest contributor after last year's transitional phase [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in driving revenue growth, with "Sodium Dexamethasone Injection" and "Nacogdocevir Calcium Injection" recording growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]

Group 1 - The core viewpoint of the article highlights the steady growth of Lee's Pharmaceutical Holdings Limited, with a revenue of HKD 695 million for the first half of 2025, representing a 5.5% increase compared to the same period last year [1] - The company's profit attributable to shareholders for the first half of 2025 was HKD 67.185 million, reflecting a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and strengthened operational capabilities [1] - Earnings per share for the company stood at HKD 0.1141 [1] Group 2 - The company holds a 65% stake in its subsidiary, China Oncology Medical Limited (COF), which focuses on research and development in oncology, particularly in the field of immuno-oncology therapies [1] - COF has established a robust pipeline of oncology assets, including six innovative assets and four generic drugs, developed through a combination of internal research and licensing agreements [1] - In July 2025, the injection of Socazoli was approved by the National Medical Products Administration for a new indication, marking its second approved indication after initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

智通财经APP讯，李氏大药厂(00950)发布截至2025年6月30日止6个月中期业绩，该集团取得收益6.95亿 港元，同比增加5.5%;公司拥有人应占溢利6718.5万港元，同比增加7.5%;每股盈利11.41港仙，拟派发中 期股息每股2.2港仙。 公告称，收益增加主要由本集团产品组合稳健的销售表现所带动。在各项罕见病及专科产品中，曲前列 尼尔注射液《芮旎尔®》取得31.4%的强劲增长，而《布累迪宁®》则上升12.9%。在引进产品的传统组 合中，《菲普利®》取得33.3%的显著增长，经去年的过渡阶段后再度成为贡献最大的产品。集中带量 采购(药品集采)计划下的产品在推动收益增长方面亦发挥重要作用，磺达肝癸钠注射液《立畅青®》及 那曲肝素钙注射液《立腾菁®》分别取得18.8%及11.3%的增长。此等产品表现改善为整体收益增长提供 支持，并有助抵销回顾期内若干其他产品销售放缓的影响。 ...

第 1 頁 共 2 頁 v 1.1.1 EF001 | 發行人所發行上市權證/可轉換債券的相關信息 | | | --- | --- | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 其他信息 | 不適用 | | 發行人董事 | | | 於本公佈日期，李小芳女士（主席）及李燁妮女士為執行董事；李小羿博士、James Charles Gale先生及黃瑞瑨先生為非執行董 | | | 事；而陳友正博士、蔣綺華女士及詹華強博士為獨立非執行董事。 | | EF001 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 李氏大藥廠控股有限公司 | | 股份代號 | 00950 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至 ...